{"id":"W4206341203","doi":"10.1200/jco.2022.40.4_suppl.tps216","title":"GOBLET: A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic gastrointestinal cancers exploring treatment combinations with pelareorep and atezolizumab.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"Oncolytics Biotech","keywords":"Atezolizumab; Medicine; Blockade; Immune checkpoint; Oncology; Cancer; Pembrolizumab; Colorectal cancer; Internal medicine; Cancer research; Immunotherapy; Melanoma; Receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001343827,0.001130524,0.001669452,0.0005550415,0.000258108,0.001316672,0.0006918906,0.001470359,0.006004316],"category_scores_gemma":[0.0007005912,0.0004375731,0.00146599,0.0003996893,0.0007124416,0.0009415842,0.000429071,0.003059592,0.001303571],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009086689,"about_ca_system_score_gemma":0.001129684,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006091523,"about_ca_topic_score_gemma":0.002156483,"domain_scores_codex":[0.9996873,0.00009035625,0.00001154755,0.00007568175,0.00007483249,0.00006024312],"domain_scores_gemma":[0.9996161,0.0000370184,0.00009646807,0.00002947384,0.00002911729,0.0001917405],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.385358,0.06252676,0.01077054,0.003833999,0.00377819,0.0009650057,0.0005239276,0.004662775,0.215029,0.001437465,0.02020927,0.2909052],"study_design_scores_gemma":[0.3594772,0.5660461,0.02014085,0.0002366693,0.002013794,0.002342461,0.0002323922,0.002862141,0.01626839,0.001228664,0.0290461,0.0001053257],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9733772,0.01031065,0.001779689,0.001331533,0.0002630375,0.004493346,0.002890814,0.0003819759,0.005171635],"genre_scores_gemma":[0.9656798,0.006634535,0.004791876,0.002741491,0.0001891569,0.004346646,0.006006282,0.000133115,0.009477109],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006004316,"threshold_uncertainty_score":0.02008641,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2138609810329056,"score_gpt":0.4807949382890939,"score_spread":0.2669339572561883,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}